Pharmacological treatment of obesity in patients with polycystic ovary syndrome

Journal of Obesity

Volumn 2011, Issue , 2011, Pages

  Kahal, Hassan ^a,b   Atkin, Stephen L ^a   Sathyapalan, Thozhukat ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84869880616     PISSN: 20900708     EISSN: 20900716     Source Type: Journal    
DOI: 10.1155/2011/402052     Document Type: Article

References (70)

1. Azziz R., Woods K. S., Reyna R., Key T. J., Knochenhauer E. S., Yildiz B. O., The prevalence and features of the polycystic ovary syndrome in an unselected population. Journal of Clinical Endocrinology and Metabolism 2004 89 6 2745 2749 2-s2.0-2942642477 10.1210/jc.2003-032046 (Pubitemid 38766360)
2. Knochenhauer E. S., Key T. J., Kahsar-Miller M., Waggoner W., Boots L. R., Azziz R., Prevalence of the polycystic ovary syndrome in unselected black and white women of the Southeastern United States: a prospective study. Journal of Clinical Endocrinology and Metabolism 1998 83 9 3078 3082 2-s2.0-0031773509 10.1210/jc.83.9.3078 (Pubitemid 28500937)
3. Diamanti-Kandarakis E., Kouli C. R., Bergiele A. T., Filandra F. A., Tsianateli T. C., Spina G. G., Zapanti E. D., Bartzis M. I., A survey of the polycystic ovary syndrome in the Greek Island of Lesbos: hormonal and metabolic profile. Journal of Clinical Endocrinology and Metabolism 1999 84 11 4006 4011 2-s2.0-0033345349 (Pubitemid 30644187)
4. Asunción M., Calvo R. M., San Millá N J. L., Sancho J., Avila S., Escobar-Morreale H. F., A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. Journal of Clinical Endocrinology and Metabolism 2000 85 7 2434 2438 2-s2.0-0034457559 10.1210/jc.85.7.2434 (Pubitemid 32269197)
5. Balen A. H., Conway G. S., Kaltsas G., Techatraisak K., Manning P. J., West C., Jacobs H. S., Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Human Reproduction 1995 10 8 2107 2111 2-s2.0-0029047506
6. Glueck C. J., Dharashivkar S., Wang P., Zhu B., Gartside P. S., Tracy T., Sieve L., Obesity and extreme obesity, manifest by ages 20-24 years, continuing through 32-41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy. European Journal of Obstetrics Gynecology and Reproductive Biology 2005 122 2 206 212 2-s2.0-26444434868 10.1016/j.ejogrb.2005.03.010 (Pubitemid 41430458)
7. Fauser B. C. J. M., Tarlatzis., Fauser., Chang., Aziz., Legro., Dewailly., Franks., Balen., Bouchard., Dahlgren., Devoto., Diamanti., Dunaif., Filicori., Homburg., Ibanez., Laven., Magoffin., Nestler., Norman., Pasquali., Pugeat., Strauss., Tan., Taylor., Wild., Wild., Guzik., Ehrmann., Lobo., Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Human Reproduction 2004 19 1 41 47 2-s2.0-0346186090 10.1093/humrep/deh098 (Pubitemid 38072004)
8. Zawadzki J. K., Dunaif A., Dunaif A., Givens J. R., Haseltine F. P., Merriam G. R., Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Polycystic Ovary Syndrome 1992 Oxford, UK Blackwell 59 69
9. Franks S., Diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. Journal of Clinical Endocrinology and Metabolism 2006 91 3 786 789 2-s2.0-33644829109 10.1210/jc.2005-2501 (Pubitemid 43357737)
10. Dunaif A., Segal K. R., Futterweit W., Dobrjansky A., Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989 38 9 1165 1174 2-s2.0-0024437305 (Pubitemid 19250404)
11. Scherer P. E., Williams S., Fogliano M., Baldini G., Lodish H. F., A novel serum protein similar to C1q, produced exclusively in adipocytes. Journal of Biological Chemistry 1995 270 45 26746 26749 2-s2.0-0028787490 10.1074/jbc.270.45.26746
12. Toulis K. A., Goulis D. G., Farmakiotis D., Georgopoulos N. A., Katsikis I., Tarlatzis B. C., Papadimas I., Panidis D., Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Human Reproduction Update 2009 15 3 297 307 2-s2.0-64549160599 10.1093/humupd/dmp006
13. O'Connor A., Phelan N., Kyaw Tun T., Boran G., Gibney J., Roche H. M., High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance. Journal of Clinical Endocrinology and Metabolism 2010 95 3 1378 1385 2-s2.0-77749270628 10.1210/jc.2009-1557
14. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R. E., Tataranni P. A., Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. Journal of Clinical Endocrinology and Metabolism 2001 86 5 1930 1935 2-s2.0-0034999667 10.1210/jc.86.5.1930 (Pubitemid 32472900)
15. Mantzoros C. S., The role of leptin in human obesity and disease: a review of current evidence. Annals of Internal Medicine 1999 130 8 671 680 2-s2.0-0033586747 (Pubitemid 29196202)
16. Carmina E., Orio F., Palomba S., Cascella T., Longo R. A., Colao A. M., Lombardi G., Lobo R. A., Evidence for altered adipocyte function in polycystic ovary syndrome. European Journal of Endocrinology 2005 152 3 389 394 2-s2.0-15944363757 10.1530/eje.1.01868 (Pubitemid 40439491)
17. Glintborg D., Andersen M., Hagen C., Frystyk J., Hulstrøm V., Flyvbjerg A., Hermann A. P., Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. European Journal of Endocrinology 2006 155 2 337 345 2-s2.0-33747633975 10.1530/eje.1.02207 (Pubitemid 44269452)
18. Atamar A., Demir B., Bayhan G., Atamer Y., Ilhan N., Akkuş Z., Serum levels of leptin and homocysteine in women with polycystic ovary syndrome and its relationship to endocrine, clinical and metabolic parameters. Journal of International Medical Research 2008 36 1 96 105 2-s2.0-39149085035 (Pubitemid 351255975)
19. Li M. G., Ding G. L., Chen XI. J., Lu XI. P., Dong LI. J., Dong M. Y., Yang X. F., Lu X. E., Huang H. F., Association of serum and follicular fluid leptin concentrations with granulosa cell phosphorylated signal transducer and activator of transcription 3 expression in fertile patients with polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism 2007 92 12 4771 4776 2-s2.0-36849071397 10.1210/jc.2007-0978 (Pubitemid 350223459)
20. Steppan C. M., Bailey S. T., Bhat S., Brown E. J., Banerjee R. R., Wright C. M., Patel H. R., Ahima R. S., Lazar M. A., The hormone resistin links obesity to diabetes. Nature 2001 409 6818 292 293
21. Mu H., Ohashi R., Yan S., Chai H., Yang H., Lin P., Yao Q., Chen C., Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovascular Research 2006 70 1 146 157 2-s2.0-33645048165 10.1016/j.cardiores.2006.01.015
22. Virtue S., Vidal-Puig A., It's not how fat you are, it's what you do with it that counts. PLoS Biology 2008 6 9, article e237 2-s2.0-54749114466 10.1371/journal.pbio.0060237
23. de Zegher F., Lopez-Bermejo A., Ibáñez L., Adipose tissue expandability and the early origins of PCOS. Trends in Endocrinology and Metabolism 2009 20 9 418 423 2-s2.0-72049087477 10.1016/j.tem.2009.06.003
24. Meirow D., Yossepowitch O., Rosler A., Brzezinski A., Schenker J. G., Laufer N., Raz I., Insulin resistant and non-resistant polycystic ovary syndrome represent two clinical and endocrinological subgroups. Human Reproduction 1995 10 8 1951 1956 2-s2.0-0029079779
25. Ehrmann D. A., Cavaghan M. K., Barnes R. B., Imperial J., Rosenfield R. L., Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999 22 1 141 146 2-s2.0-0344286476 10.2337/diacare.22.1.141 (Pubitemid 29028311)
26. Talbott E., Guzick D., Clerici A., Berga S., Detre K., Weimer K., Kuller L., Coronary heart disease risk factors in women with polycystic ovary syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 1995 15 7 821 826 2-s2.0-0029009180
27. Diamanti-Kandarakis E., Alexandraki K., Protogerou A., Piperi C., Papamichael C., Aessopos A., Lekakis J., Mavrikakis M., Metformin administration improves endothelial function in women with polycystic ovary syndrome. European Journal of Endocrinology 2005 152 5 749 756 2-s2.0-19744365285 10.1530/eje.1.01910 (Pubitemid 40744544)
28. Rajendran S., Willoughby S. R., Chan W. P. A., Liberts E. A., Heresztyn T., Saha M., Marber M. S., Norman R. J., Horowitz J. D., Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis 2009 204 2 509 514 2-s2.0-67349217369 10.1016/j.atherosclerosis.2008.09.010
29. Dahlgren E., Janson P. O., Johansson S., Lapidus L., Oden A., Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstetricia et Gynecologica Scandinavica 1992 71 8 599 604 2-s2.0-0027080247 (Pubitemid 23050339)
30. Wild S., Pierpoint T., McKeigue P., Jacobs H., Cardiovascular disease in women with polycystic ovary syndrome at long- term follow-up: a retrospective cohort study. Clinical Endocrinology 2000 52 5 595 600 2-s2.0-0034078044 10.1046/j.1365-2265.2000.01000.x (Pubitemid 30337085)
31. Shaw L. J., Merz C. N. B., Azziz R., Stanczyk F. Z., Sopko G., Braunstein G. D., Kelsey S. F., Kip K. E., Cooper-DeHoff R. M., Johnson B. D., Vaccarino V., Reis S. E., Bittner V., Hodgson T. K., Rogers W., Pepine C. J., Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored women's ischemia syndrome evaluation. Journal of Clinical Endocrinology and Metabolism 2008 93 4 1276 1284 2-s2.0-42049083794 10.1210/jc.2007-0425 (Pubitemid 351519721)
32. Apridonidze T., Essah P. A., Iuorno M. J., Nestler J. E., Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2005 90 4 1929 1935 2-s2.0-17844367331 10.1210/jc.2004-1045 (Pubitemid 40586223)
33. Douchi T., Ijuin H., Nakamura S., Oki T., Yamamoto S., Nagata Y., Body fat distribution in women with polycystic ovary syndrome. Obstetrics and Gynecology 1995 86 4, part 1 516 519 2-s2.0-0029064786 10.1016/0029-7844(95) 00250-U
34. Acien P., Quereda F., Matallin P., Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertility and Sterility 1999 72 1 32 40 10.1016/S0015-0282(99)00184-3 (Pubitemid 29300258)
35. Álvarez-Blasco F., Botella-Carretero J. I., San Millán J. L., Escobar-Morreale H. F., Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Archives of Internal Medicine 2006 166 19 2081 2086 2-s2.0-33750333937 10.1001/archinte.166.19.2081 (Pubitemid 44631395)
36. Yildiz B. O., Knochenhauer E. S., Azziz R., Impact of obesity on the risk for polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2008 93 1 162 168 2-s2.0-38149096151 10.1210/jc.2007-1834
37. Moran L. J., Noakes M., Clifton P. M., Tomlinson L., Galletly C., Norman R. J., Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2004 88 2 812 819
38. Huber-Buchholz M. M., Carey D. G. P., Norman R. J., Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. Journal of Clinical Endocrinology and Metabolism 1999 84 4 1470 1474 2-s2.0-0033346579 (Pubitemid 30644417)
39. Moran L. J., Noakes M., Clifton P. M., Wittert G. A., Williams G., Norman R. J., Short-term meal replacements followed by dietary macronutrient restriction enhance weight loss in polycystic ovary syndrome. American Journal of Clinical Nutrition 2006 84 1 77 87 2-s2.0-33747405119 (Pubitemid 44699174)
40. Holte J., Bergh T., Berne C., Wide L., Lithell H., Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1995 80 9 2586 2593
41. Sabuncu T., Harma M., Harma M., Nazligul Y., Kilic F., Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertility and Sterility 2003 80 5 1199 1204 2-s2.0-0242577363 10.1016/S0015-0282(03)02162-9 (Pubitemid 37377751)
42. Sathyapalan T., Cho LI. W., Kilpatrick E. S., Coady A. M., Atkin S. L., A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. Clinical Endocrinology 2008 69 6 931 935 2-s2.0-55949087098 10.1111/j.1365-2265.2008.03260.x
43. Guerciolini R., Mode of action of orlistat. International Journal of Obesity 1997 21 supplement 3 S12 S23 (Pubitemid 27271984)
44. Padwal R., rpadwal@yahoo.com Li S. K., Lau D. C. W., Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. International Journal of Obesity 2003 27 12 1437 1446 10.1038/sj.ijo.0802475 (Pubitemid 38019154)
45. Torgerson J. S., Hauptman J., Boldrin M. N., Sjöström L., XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004 27 1 155 161 2-s2.0-1042303480 10.2337/diacare.27.1.155 (Pubitemid 38196725)
46. Jayagopal V., Kilpatrick E. S., Holding S., Jennings P. E., Atkin S. L., Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism 2005 90 2 729 733 2-s2.0-14044255980 10.1210/jc.2004-0176 (Pubitemid 40279187)
47. Cho L. W., Kilpatrick E. S., Keevil B. G., Coady A. M., Atkin S. L., Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clinical Endocrinology 2009 70 2 233 237 2-s2.0-58549097078 10.1111/j.1365-2265.2008. 03309.x
48. Diamanti-Kandarakis E., Katsikis I., Piperi C., Alexandraki K., Panidis D., Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clinical Endocrinology 2007 66 1 103 109 2-s2.0-33845625310 10.1111/j.1365-2265.2006.02693.x (Pubitemid 44952501)
49. Diamanti-Kandarakis E., Christakou C. D., Kandaraki E., Economou F. N., Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. European Journal of Endocrinology 2010 162 2 193 212 2-s2.0-75149162547 10.1530/EJE-09-0733
50. Setter S. M., Iltz J. L., Thams J., Campbell R. K., Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clinical Therapeutics 2003 25 12 2991 3026 2-s2.0-0347933028 10.1016/S0149-2918(03)90089-0 (Pubitemid 38096142)
51. Fleming R., Hopkinson Z. E., Michael Wallace A., Greer I. A., Sattar N., Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2002 87 2 569 574 2-s2.0-0036170744 10.1210/jc.87.2.569 (Pubitemid 34158220)
52. Moghetti P., Castello R., Negri C., Tosi F., Perrone F., Caputo M., Zanolin E., Muggeo M., Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. Journal of Clinical Endocrinology and Metabolism 2000 85 1 139 146 2-s2.0-0034458234 10.1210/jc.85.1.139 (Pubitemid 32268804)
53. Trolle B., Flyvbjerg A., Kesmodel U., Lauszus F. F., Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Human Reproduction 2007 22 11 2967 2973 2-s2.0-42949103243 10.1093/humrep/dem271 (Pubitemid 351696807)
54. Lord J. M., Flight I. H. K., Norman R. J., Metformin in polycystic ovary syndrome: systematic review and meta-analysis. British Medical Journal 2003 327 7421 951 955 2-s2.0-0142247208 (Pubitemid 37330397)
55. Maciel G. A. R., Soares J. M., Alves Da Motta E. L., Haidar M. A., Rodrigues De Lima G., Baracat E. C., Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertility and Sterility 2004 81 2 355 360 2-s2.0-1242306504 10.1016/j.fertnstert.2003.08. 012 (Pubitemid 38223916)
56. Harborne L. R., Sattar N., Norman J. E., Fleming R., Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. Journal of Clinical Endocrinology and Metabolism 2005 90 8 4593 4598 2-s2.0-23844436916 10.1210/jc.2004-2283 (Pubitemid 41159348)
57. Sathyapalan T., Cho L. W., Kilpatrick E. S., Coady A. M., Atkin S. L., Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS). Clinical Endocrinology 2009 70 1 124 128 2-s2.0-58149164733 10.1111/j.1365-2265.2008. 03345.x
58. Howlett H. C. S., Bailey C. J., A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Safety 1999 20 6 489 503 2-s2.0-0032985166 10.2165/00002018-199920060-00003 (Pubitemid 29296595)
59. Brubaker P. L., Anini Y., Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Canadian Journal of Physiology and Pharmacology 2003 81 11 1005 1012 2-s2.0-0347990354 10.1139/y03-107 (Pubitemid 38045829)
60. Drucker D. J., The biology of incretin hormones. Cell Metabolism 2006 3 3 153 165 2-s2.0-33644618433 10.1016/j.cmet.2006.01.004
61. Mari A., Degn K., Brock B., Rungby J., Ferrannini E. L. E., Schmitz O., Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on β -cell function in normal living conditions. Diabetes Care 2007 30 8 2032 2033 2-s2.0-34547684649 10.2337/dc07-0310 (Pubitemid 47219415)
62. Willms B., Werner J., Holst J. J., Ørskov C., Creutzfeldt W., Nauck M. A., Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. Journal of Clinical Endocrinology and Metabolism 1996 81 1 327 332 2-s2.0-0030068620
63. Flint A., Raben A., Ersbøll A. K., Holst J. J., Astrup A., The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. International Journal of Obesity 2001 25 6 781 792 (Pubitemid 32601369)
64. Kinzig K. P., D'Alessio D. A., Seeley R. J., The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. Journal of Neuroscience 2002 22 23 10470 10476 2-s2.0-0036896243 (Pubitemid 35416883)
65. Elkind-Hirsch K., Marrioneaux O., Bhushan M., Vernor D., Bhushan R., Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2008 93 7 2670 2678 2-s2.0-47549095688 10.1210/jc.2008-0115 (Pubitemid 352008535)
66. Astrup A., Rössner S., Van Gaal L., Rissanen A., Niskanen L., Al Hakim M., Madsen J., Rasmussen M. F., Lean M. E., Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. The Lancet 2009 374 9701 1606 1616 2-s2.0-70350619609 10.1016/S0140-6736(09)61375-1
67. Buse J. B., Rosenstock J., Sesti G., Schmidt W. E., Montanya E., Brett J. H., Zychma M., Blonde L., Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). The Lancet 2009 374 9683 39 47 2-s2.0-67649666737 10.1016/S0140-6736(09)60659-0
68. Parks M., Rosebraugh C., Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. New England Journal of Medicine 2010 362 9 774 777 2-s2.0-77649294607 10.1056/NEJMp1001578
69. Eid G. M., Cottam D. R., Velcu L. M., Mattar S. G., Korytkowski M. T., Gosman G., Hindi P., Schauer P. R., Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. Surgery for Obesity and Related Diseases 2005 1 2 77 80 2-s2.0-33646445745 10.1016/j.soard.2005.02.008
70. Escobar-Morreale H. F., hescobarm.hrc@salud.madrid.org Botella-Carretero J. I., Álvarez-Blasco F., Sancho J., San Millán J. L., The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. Journal of Clinical Endocrinology and Metabolism 2005 90 12 6364 6369 10.1210/jc.2005-1490 (Pubitemid 41759284)